FOI_9200

Internal Reference Number: FOI_9200

Date Request Received: 02/02/2026 00:00:00

Date Request Replied To: 27/02/2026 00:00:00

This response was sent via: By Email

Request Summary: Treatment of Waldenström macroglobulinaemia (WM) & Marginal zone lymphoma (MZL)

Request Category: Private Individuals


Question Number 1: Does your Trust treat patients for the two following conditions? Yes/No Waldenström macroglobulinaemia (WM) (ICD-10 C88.0) Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)

Answer To Question 1: Yes

Question Number 2: If yes to q1 How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions? Waldenström macroglobulinaemia (WM) Marginal zone lymphoma (MZL)

Answer To Question 2: WM = 13 patients MZL = Concealed (<=5) due to low numbers

Question Number 3: Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials. Waldenström macroglobulinaemia (WM) Marginal zone lymphoma (MZL)

Answer To Question 3: At SFT there is one Clinical Trial for WM (IRAS Number 264348) with fewer than 5 participants in follow up. There is also one Clinical Trial for MZL (IRAS Number 1007959) with fewer than 5 participants randomised.

Question Number 4: If no to Q1 Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

Answer To Question 4: Not applicable

Question Number 5: How many patients (and new patients* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025? *Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024. - see table attached to complete

Answer To Question 5: Please see attached To accompany this answer to question 5 please also see the documents listed below: 13500 - FOI_9200 - Waldenström macroglobulinaemia (WM) (ICD-10 C88.0) - answer sheet - FOR ISSUE.pdf

Question Number 6: How many patients (and new patients* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025? See table attached to complete.

Answer To Question 6: Please see attached To accompany this answer to question 6 please also see the documents listed below: 13500 - FOI_9200 - Marginal zone lymphoma (MZL) (ICD-10 C83.0 C88.4) - FOR ISSUE.pdf
Please see Attachments:



To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.